Hirtle Callaghan & Co’s Labcorp LH Stock Holding History

Hirtle Callaghan & Co’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,300	Closed	-$295K	–	102
2023 Q4	$295K	Hold	1,300	–	–	0.01%	82
2023 Q3	$261K	Buy	+1,300	New	+$274K	0.01%	77

Other funds holding LH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hirtle Callaghan & Co's LH Position: Q1 2024 in Review

Hirtle Callaghan & Co sold out of Labcorp (LH) in Q1 2024, closing a stake of 1,300 shares — an estimated $295K sold.

Hirtle Callaghan & Co first reported a position in LH in Q3 2023 and held it in 2 quarters. The position peaked at $295K in Q4 2023. 927 funds tracked by Wall St. Rank hold LH as of Q1 2024.

Hirtle Callaghan & Co reported no remaining Labcorp position as of Q1 2024 after selling out during the quarter.
Hirtle Callaghan & Co sold 1,300 Labcorp shares in Q1 2024, an estimated $295K.
Hirtle Callaghan & Co first reported a position in Labcorp in Q3 2023 and held it in 2 quarters.
Hirtle Callaghan & Co's Labcorp position peaked at $295K in Q4 2023.
927 funds tracked by Wall St. Rank held Labcorp as of Q1 2024.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2024, filed 10 May 2024.